We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
New Jersey-based Merck & Co. Inc. (MRK - Free Report) a global research-driven pharmaceutical products company. Well known products in Merck’s portfolio include Remicade, Nasonex, Simponi, Vytorin and Zetia, Januvia and Janumet, Isentress, PegIntron, Maxalt, Cosopt/Trusopt, Temodar, Emend, Keytruda, Cozaar/Hyzaar, Zocor, Proscar, ProQuad, Gardasil, RotaTeq, Zostavax and NuvaRing.
However, like many of its peers, Merck is facing headwinds in the form of generic competition for several key products. The company sold off its Consumer Care business to Bayer for $14.2 billion in Oct 2014. Meanwhile, Merck acquired hepatitis C virus focused company Idenix Pharmaceuticals in Aug 2014 and Cubist Pharmaceuticals in 2015. Merck is also focusing on immuno-oncology.
Merck has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 4.30%. Estimate movement has been mixed over the past 60 days.
Currently, Merck has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Merck surpassed fourth-quarter 2016 earnings expectations. The company reported EPS of 89 cents while our consensus called for EPS of 88 cents.
Revenues Miss: Revenues in the reported quarter came below expectations. Merck posted revenues of $10.12 billion below our consensus estimate of $10.20 billion.
2017 Outlook: Merck issued 2017 earnings and revenues guidance. The company expects adjusted earnings in the range of $3.72 to $3.87 per share, including approximately 2% negative foreign exchange impact. The Zacks Consensus Estimate stood at $3.82 per share.
Merck expects revenue in the range of $38.6 billion - $40.1 billion, including negative currency impact of approximately 2%. The sales guidance fell slightly short of the Zacks Consensus Estimate of $40.17 billion.
Stock Price Impact: Shares were in-active in pre-market trading.
Check back later for our full write up on this MRK earnings report!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Tops Q4 Earnings, Misses Sales Estimates
New Jersey-based Merck & Co. Inc. (MRK - Free Report) a global research-driven pharmaceutical products company. Well known products in Merck’s portfolio include Remicade, Nasonex, Simponi, Vytorin and Zetia, Januvia and Janumet, Isentress, PegIntron, Maxalt, Cosopt/Trusopt, Temodar, Emend, Keytruda, Cozaar/Hyzaar, Zocor, Proscar, ProQuad, Gardasil, RotaTeq, Zostavax and NuvaRing.
However, like many of its peers, Merck is facing headwinds in the form of generic competition for several key products. The company sold off its Consumer Care business to Bayer for $14.2 billion in Oct 2014. Meanwhile, Merck acquired hepatitis C virus focused company Idenix Pharmaceuticals in Aug 2014 and Cubist Pharmaceuticals in 2015. Merck is also focusing on immuno-oncology.
Merck has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 4.30%. Estimate movement has been mixed over the past 60 days.
Merck & Company, Inc. Price and Consensus
Merck & Company, Inc. Price and Consensus | Merck & Company, Inc. Quote
Currently, Merck has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Merck surpassed fourth-quarter 2016 earnings expectations. The company reported EPS of 89 cents while our consensus called for EPS of 88 cents.
Revenues Miss: Revenues in the reported quarter came below expectations. Merck posted revenues of $10.12 billion below our consensus estimate of $10.20 billion.
2017 Outlook: Merck issued 2017 earnings and revenues guidance. The company expects adjusted earnings in the range of $3.72 to $3.87 per share, including approximately 2% negative foreign exchange impact. The Zacks Consensus Estimate stood at $3.82 per share.
Merck expects revenue in the range of $38.6 billion - $40.1 billion, including negative currency impact of approximately 2%. The sales guidance fell slightly short of the Zacks Consensus Estimate of $40.17 billion.
Stock Price Impact: Shares were in-active in pre-market trading.
Check back later for our full write up on this MRK earnings report!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>